BioNTech's malaria vaccine effort is based on its mRNA technology, which was employed during the pandemic to quickly develop COVID-19 vaccines, by prompting the human body to make a protein that ...

The World Health Organization (WHO) estimates that there were around 263 million malaria cases in 2023 and 597,000 deaths.

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for malaria prevention.

The U.S. Food and Drug Administration has placed a clinical hold on BioNTech's early-to-mid stage trial of an experimental malaria vaccine, the drugmaker said in a filing, sending its U.S.-listed ...

BioNTech has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on Friday.

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the ...

The FDA placed a clinical hold on BioNTech’s Phase 1/2a trial for its investigational RNA-based malaria vaccine, BNT165e. BioNTech paused the study and is working with the FDA to address its ...

BioNTech, best known for delivering the world’s first Covid-19 vaccine given outside of clinical trials with Pfizer, is hoping to turn its mRNA technology against malaria.

BERLIN – BioNTech SE has begun human trials on a vaccine for malaria, a fresh test for the messenger RNA technology that powered the most successful immunisations against Covid-19.. The first ...

BioNTech has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on Friday. The Phase 1 trial is ...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the ...